TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4A(Homo sapiens (Human))
Basilea Pharmaceutica
US Patent
Basilea Pharmaceutica
US Patent
Affinity DataIC50: 0.100nMAssay Description:PDEs specifically hydrolyze cAMP and/or cGMP and release the product AMP and/or GMP. The potency of PDE inhibition by test compounds is determined wi...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4A(Homo sapiens (Human))
Basilea Pharmaceutica
US Patent
Basilea Pharmaceutica
US Patent
Affinity DataIC50: 31nMAssay Description:PDEs specifically hydrolyze cAMP and/or cGMP and release the product AMP and/or GMP. The potency of PDE inhibition by test compounds is determined wi...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4A(Homo sapiens (Human))
Basilea Pharmaceutica
US Patent
Basilea Pharmaceutica
US Patent
Affinity DataIC50: 35nMAssay Description:PDEs specifically hydrolyze cAMP and/or cGMP and release the product AMP and/or GMP. The potency of PDE inhibition by test compounds is determined wi...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4A(Homo sapiens (Human))
Basilea Pharmaceutica
US Patent
Basilea Pharmaceutica
US Patent
Affinity DataIC50: 43nMAssay Description:PDEs specifically hydrolyze cAMP and/or cGMP and release the product AMP and/or GMP. The potency of PDE inhibition by test compounds is determined wi...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4A(Homo sapiens (Human))
Basilea Pharmaceutica
US Patent
Basilea Pharmaceutica
US Patent
Affinity DataIC50: 71nMAssay Description:PDEs specifically hydrolyze cAMP and/or cGMP and release the product AMP and/or GMP. The potency of PDE inhibition by test compounds is determined wi...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4A(Homo sapiens (Human))
Basilea Pharmaceutica
US Patent
Basilea Pharmaceutica
US Patent
Affinity DataIC50: 300nMAssay Description:PDEs specifically hydrolyze cAMP and/or cGMP and release the product AMP and/or GMP. The potency of PDE inhibition by test compounds is determined wi...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4A(Homo sapiens (Human))
Basilea Pharmaceutica
US Patent
Basilea Pharmaceutica
US Patent
Affinity DataIC50: 876nMAssay Description:PDEs specifically hydrolyze cAMP and/or cGMP and release the product AMP and/or GMP. The potency of PDE inhibition by test compounds is determined wi...More data for this Ligand-Target Pair